Summary
Peptic ulcer disease (PUD) is a common medical problem costing billions of dollars annually around the world. Since the availability of the first histamine H2-receptor antagonist, cimetidine, many economic analyses have been conducted to compare the impact of this drug class on resource consumption.
H2-Antagonists have been shown to reduce mortality, hospitalisations, ambulatory care visits and endoscopy use caused by PUD. Because of changing risk factors and variations in diagnosis, it remains controversial whether these drugs have had a long term impact on PUD incidence and prevalence. Three studies conducted after the introduction of cimetidine showed it to reduce total direct medical healthcare expenditures, despite increases in drug costs.
Studies investigating the short term treatment of PUD show mixed results because of diverse study designs and different comparator drugs. No specific therapy appears consistently superior economically because of variations in population studies, ulcer relapse rates and drug acquisition costs. However, maintenance therapy for PUD has been shown to be cost-effective. When compared with surgery — an extremely efficacious option — maintenance therapy (both daily and intemittent) is cost-effective over at least a 10-year period. Within the maintenance therapy options, daily ranitidine has been shown to be more cost-effective than intermittent therapy for up to 2 years.
Omeprazole is the least costly and most efficacious treatment for gastroesophageal reflux disease (GORD or GERD) compared with ranitidine and/or lifestyle modification alone. It has also been shown that the costs for empirical treatment of GORD are offset by the costs of additional investigation of those who do not have the disease. Thus the decision of whether to treat empirically should be based on physician and patient preferences. and not on costs.
The use of misoprostol for ulcers caused by nonsteroidal anti-inflammatory drugs is somewhat controversiaL Three studies examining the short term (3-month) costs of misoprostol generally show it to be cost saving or cost neutral. Misoprostol is consistently more cost beneficial in elderly or other high risk: patients. Results are highly sensitive, however, to several parameters, such as patient type. ulcer severity and rate, drug costs and patient compliance. One study examining prophylaxis using misoprostol over 1 year showed it to be a generally expensive therapy for primary prevention, but was more cost effective for those with a proven GI bleed in the previous year.
Cost-minimisation studies conducted within the hospital setting explore the cost savings realised from limiting the formulary to the least expensive therapy. as well as encouraging the use of oral medication in place of intravenous therapy. Results vary widely depending upon drug acquisition cost and extent of inappropriate prescribing of intravenous therapy.
More research is needed which examines quality of life, effects on health-related productivity changes, and the most cost-effective option for the treatment of Helicobacter pylori. Ideally. these analyses will be based on prospective comparative trials conducted over longer durations in order to account for all appropriate benefits and costs of drug therapy.
Similar content being viewed by others
References
Algozzine GJ, Sprenger RL, Caselnova DA, et al. Pharmacy intern intervention to reduce costs associated with histamine H2-antagonist therapy. American Journal of Hospital Pharmacy 46: 1183–1184, 1989
Ashton T. Cost-effectiveness of alternative medications in the treatment of duodenal ulcer. Scandinavian Journal of Gastroenterology 26: 82–88, 1991
Baciewicz AM. Conversion of intravenous ranitidine to oral therapy. DICP Annals of Pharmacotherapy 25: 251–252, 1991
Barradell LB, Whittington R, Bentleld P. Misoprostol. Pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. PharmacoEconomics 3: 140–171, 1993
Berkowitz HS. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist. American Journal of Hospital Pharmacy 49: 134–135, 1992
Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 149: 1019–1022, 1989
Bloom BS. Cross-national changes in the effects of peptic ulcer disease. Annals of Internal Medicine 114: 558–562, 1991
Bloom BS, Gessner U. Mortality, hospitalization, and work loss due to peptic ulcer and gastritis/duodenitis in the Federal Republic of Germany. International Journal of Technology Assessment in Health Care 5: 215–226, 1989
Bloom BS, Fendrick MA, Ramsey SD. Changes in peptic ulcer and gastritis/duodenitis in Great Britain, 1970-1985. Journal of Clinical Gastroenterology 12: 100–108, 1990
Bloom BS, Fox NA, Jacobs J. Patterns of care and expenditures by California Medicaid for peptic ulcer and other acid-related disorders. Journal of Clinical Gastroenterology 11: 615–620, 1989
Brodin HFT, Hedenbro JL, Liedherg G. Ulcer surgery made less expensive; a cost development study: 1963, 1973, and 1978. Annals of Surgery 198: 5–8, 1983
Bulthuis R. Cimetidine and the cost of peptic ulcer in the Netherlands. Effective Health Care 6: 297–311, 1984
Caldwell DR, Davis SK. Use of staff pharmacists to reduce the inappropriate use of parenteral histamine-2 antagonist therapy. Hospital Pharmacy 22: 1205–1209, 1987
Coppola P. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital. Hospital Pharmacy 26: 126–129, 1991
Culyer AJ, Maynard AK. Cost-effectiveness of duodenal ulcer treatment. Social Science and Medicine 15C: 3–11, 1981
Drutnmond MF. Economic evaluation of pharmaceuticals: science or marketing? PharmacoEconomics 1: 8–13, 1992
Edelson JT, Tosteson ANA. The cost-effectiveness of misoprostol. Correspondence. Journal of the American Medical Association 265: 594–595, 1991
Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. Journal of the American Medical Association 264: 41–47, 1990
Eisenberg JM. A guide to the economic analysis of clinical practices. Journal of the American Medical Association 262: 2879–2886, 1989
Falbe WJ, Bess DT, Capers CC, et al. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonist. American Journal of Hospital Pharmacy 49: 632–633, 1992
Foulke GE, Siepler J. Antiulcer therapy: an exercise in formulary management. Journal of Clinical Gastroenterology 12 (Suppl. 2): 64S–68S, 1990
Fox N, Morton RE, Jacobs J. The cost-effectiveness of maintenance therapy for duodenal ulceration with an H2-antagonist. Alimentary Pharmacology and Therapeutics 2: 297–309, 1988
Freston JW. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection. American Journal of Gastroenterology 82: 1242–1249, 1987
Fudge KA, Moore KA, Schneider DN, et al. Change in prescribing patterns of intravenous histamme2-receptor antagonists results in significant cost savings without adversely affecting patient care. Annals of Pharmacotherapy 27: 232–234, 1993
Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for non-steroidal anti-inflammatory drug-associatcd adverse gastrointestinal events. Arthritis and Rheumatism 36: 447–459, 1993
Gamett WR. The cost-effectiveness of misoprostol for non-steroidal anti-inflammatory drug-associatcd adverse gastrointestinal events. Arthritis and Rheumatism 50 (Suppl. 1): 11S–18S, 1993
Geweke J, Weisbrod BA. Clinical evaluation vs. economic evaluation: the case of a new drug. Medical Care 20: 821–830, 1982
Glise H. Epidemiology in peptic ulcer disease: current status and future aspects. Scandinavian Journal of Gastroenterology 25 (Suppl. 175): 13–18, 1990
Goulston KJ, Dent OF, Mant A, et al. Use of H2-receptor antagonists in patients with dyspepsia and heartburn: a cost comparison. Medical Journal of Australia 155: 20–26, 1991
Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 149: 2061–2065, 1989
Hillman AL, Bloom BS. The cost-effectiveness of misoprostol. Correspondence. Journal of the American Medical Association 265: 593, 1991
Hillman AL, Bloom BS, Fendrick AM, et al. Cost and quality effects of alternative treatments for persistent gastroesophogeal reflux disease. Archives of Internal Medicine 152: 1467–1472, 1992
Hillman AL, Eisenberg JM, Pauly MF, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991
Illingworth CF, Scott LD, Jamieson RA. Acute perforated peptic ulcer. British Medical Journal 2: 617–620 and 655-658, 1944
Jensen DM. Health and economic aspects of peptic ulcer disease. American Journal of Medicine 77 (Suppl. 5): 8S–14S, 1984
Jensen DM. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists. American Journal of Medicine 81(Suppl 4B): 42S–48S, 1986
Jönsson B, Carlsson P. The effects of cimetidine on the cost of ulcer disease in Sweden. Social Science and Medicine 33: 275–282, 1991
Kirking DM, Svinte MK, Berardi RM, et al. Evaluation of direct pharmacist intervention on conversion from parenteral to oral histamine H2-receptor antagonist therapy. DICP Annals of Pharmacotherapy 25: 804, 1991
Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving nonsteroidal anti-inflammatory drags. Postgraduate Medical Journal 66: 639–646, 1990
Kong KM, Johnson WF, Anderson PO, et al. Effect of a pharmacy-based cost-containment program on cimetidine costs and use. American Journal of Hospital Pharmacy 44: 2068–2073, 1987
Kurata JH, Elashoff JD, Nogawa AN, et al. Sex and smoking differences in duodenal ulcer mortality. American Journal of Public Health 76: 700–702, 1986
Laine L. Multipolar electrocoagulation in the treatment of peptic ulcers with nonbleeding visible vessels: a prospective controlled trials. Annals of Internal Medicine 110: 510–514, 1989
Lane MR, Lee SP. Recurrence of duodenal ulcer after medical treatment. Lancet 1: 1147–1149, 1988
Lanza F, Peace KE, Zimmerman H, et al. Cost-effectiveness of cimetidine and misoprostol in peptic ulcer disease. Drug Information Journal 22: 449–457, 1988
Mead RA, McGhan WF. Use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization following continued clinical pharmacist intervention. DICP Annals of Pharmacotherapy 22: 466–469, 1988
Nishioka NS, Richter JM. Endoscopic therapy of bleeding peptic ulcers: a cost-benefit analysis. Gaslrointestinal Endoscopy 33: 277–283, 1987
Nolly RJ, Skoutakis VA. Cost considerations of intravenously administered histamines2-receptor antagonists. DICP Annais of Pharmacotherapy 23: S23–S28, 1989
O’Connor TW, Pisano D. Estimated cost savings through the use of antacid treatment as an alternative H2-histamine antagonists. Advances in Therapy 8: 305–316, 1991
Piper DW, Pym BM, Toy S, et al. The effect of maintenance cimetidine therapy on the medical, social and economic aspects of patients with chronic gastric ulcers. Medical Journal of Australia 145: 400–403, 1986
Pym B, Sandstad J, Seville P, et al. Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology 99: 27–35, 1990
Raisch DW, Bootman JL, Larson LN, et al. Improving antiulcer agent prescribing in a health maintenance organization. American Journal of Hospital Pharmacy 47: 1766–1773, 1990
Rice KM, LeRoy ML, Ivey MF, et al. Use of criteria developed before formulary addition to evaluate misoprostol use. American Journal of Hospital Pharmacy 49: 629–631, 1992
Savitsky ME, Kirking DM, Cornish LA, et al. Costs associated with the inappropriate route of administration of parenteral histamine2-receptor antagonists. DICP Annals of Pharmacotherapy 21: 885–889, 1987
Schlesinger PK, Robinson B, Layden TJ. Epidemiology considerations in peptic ulcer disease. Journal of the Association of Academy of Minor Physicians 3: 70–77, 1992
G D. Searle & Co. Misoprostol (Cytotcc®) prescribing information, Chicago, Illinois, USA, 1993
Sintonen H, Alander V. Comparing the cost-effectiveness of drug regimens in the treatment of duodenal ulcers. Journal of Health Economics 9: 85–101, 1990
Sonnenberg A. Costs of medical and surgical treatment of duodenal ulcer. Gastroenterology 96: 1445–1452, 1989
Souney PF, Stoukides CA. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists. DICP Annals of Pharmacotherapy 23: 29S–35S, 1989
Udvarhelyi IS, Colditz GA, Rai A, et al. Cost effectiveness and cost benefit analysis in the medical literature. Annals of Internal Medicine 116: 238–244, 1992
Van Deventer GM, Elashoff JD, Reedy TJ, et al. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. New England Journal of Medicine 320: 1113–1119, 1989
Van Deventer GM, Osterhaus JT. Pharmacoeconomic benefits of ranitidine maintenance therapy. Journal of Clinical Research and Pharmacoepidemiology 6: 29–37, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tucker, P.P., Nash, D.B. Formulary Management of Antiulcer Drugs. Pharmacoeconomics 5, 313–334 (1994). https://doi.org/10.2165/00019053-199405040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199405040-00006